Drug-induced hypersensitivity reactions
| | | | | | |
Abacavir
|
B*57:01
|
Hypersensitivity (all)
|
117 (29-481)
|
[14]
|
1
|
25
|
Carbamazepine
|
B*15:02
|
SJS/TEN (Han Chinese)
|
2,504 (126-49,522)
|
[4]
|
1
|
6
|
|
A*31:01
|
All phenotypes (Caucasian)
|
12.12 (4.03-20.65)
|
[17]
|
0
|
23
|
Allopurinol
|
B*58:01
|
SJS (Han Chinese)
|
580.3 (34.4-9,780.9)
| |
0
|
6
|
| |
SJS (Caucasian)
|
80 (34-187)
|
[10, 12]
| | |
Nevirapine
|
DRB1*01:01
|
Hypersensitivity (Caucasian)
|
4.8 (1.3-16.8)
|
[16]
|
3
|
52
|
Lamotrigine
|
B*38
|
SJS/TEN (Caucasian)
|
6.8 (2.6-18)
|
[12]
|
0
|
7
|
Drug-induced liver injury
| | | | | | |
Flucloxacillin
|
B*57:01
|
DILI (Caucasian)
|
80.6 (22.8-284.9)
|
[6]
|
1
|
25
|
Ximelagatran
|
DRB1*07:01
|
DILI (Caucasian)
|
4.4 (2.2-8.9)
|
[11]
|
10
|
91
|
|
DQA1*02:01
| |
4.4 (2.2-8.1)
| |
ND
|
ND
|
Lumiracoxib
|
DRB1*15:01
|
DILI (Caucasian)
|
7.5 (5.0 to 11.3)
|
[21]
|
10
|
100
|
|
DQA1*01:02
| |
6.3 (4.1 to 9.6)
| |
ND
|
ND
|
|
DQB1*06:02
| |
6.9 (4.6 to 10.3)
| |
8
|
90
|
Co-amoxiclav
|
DRB1*15:01 and
|
DILI (Caucasian)
|
2.8 (2.1 to 3.8)
|
[7, 8, 13, 18]
|
10
|
100
|
|
DQB1*06:02
| | | |
8
|
90
|
|
A*02:01
| |
2.3 (1.8 to 2.9)
| |
46
|
153
|
Antituberculosis (isoniazid, rifampicin, pyrazinamide)
|
DQB1*02:01
|
DILI (Indian)
|
1.9 (1.0 to 3.9)
|
[20]
|
20
|
143
|
Lapatinib
|
DQA1*02:01
|
DILI (Caucasian)
|
2.2 (1.1 to 5.7)
|
[22]
|
ND
|
ND
|
| | |
9.0 (3.2 to 27.4)
| | | |
|
DRB1*07:01
| |
6.9 (2.5 to 19.9)
| |
10
|
91
|
|
DQB1*02:02
| |
6.9 (2.5 to 19.6)
| |
0
|
0
|
Diclofenac
|
DRB1*13
|
DILI (Caucasian)
|
-
|
[5]
|
-
|
-
|
Clometacin
|
B*08
|
DILI
|
-
|
[19]
|
-
|
-
|
Ticlopidine
|
A*33:03
|
DILI (Japanese)
|
13.0 (4.4 to 38.6)
|
[9]
|
1
|
8
|